Glycopeptide-membrane interactions: Glycosyl enkephalin analogues adopt turn conformations by NMR and CD in amphipathic media

Journal of the American Chemical Society

Volumn 125, Issue 19, 2003, Pages 5823-5831

  Palian, Michael M ^a   Boguslavsky, V I ^a   O'Brien, David F ^a   Polt, Robin ^a  

^a University of Arizona   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDES;

CONFORMATIONS; GLUCOSE; MICELLES; MOLECULES; NUCLEAR MAGNETIC RESONANCE;

BIOLOGICAL MEMBRANES;

5 DOXYLSTEARIC ACID; CHOLESTEROL; DISACCHARIDE BETA MALTOSE; ENKEPHALIN DERIVATIVE; GLYCOPEPTIDE; LIPID; MANGANESE; MONOSACCHARIDE BETA GLUCOSE; MORPHINE; STEARIC ACID DERIVATIVE; TRISACCHARIDE BETA MALTOTRIOSE; UNCLASSIFIED DRUG; WATER;

ANALGESIC ACTIVITY; ANALYTIC METHOD; AQUEOUS SOLUTION; ARTICLE; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; CULTURE MEDIUM; DIALYSIS; DRUG CONFORMATION; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENCY; DRUG PURIFICATION; DRUG SYNTHESIS; EXPERIMENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID VESICLE; MEMBRANE; MICELLE; MOLECULAR MECHANICS; MONTE CARLO METHOD; NUCLEAR MAGNETIC RESONANCE; PROCESS MODEL; PROTEIN GLYCOSYLATION; PROTEIN INTERACTION; PROTEIN MOTIF; SPIN LABELING; STRUCTURE ANALYSIS; SURFACE PROPERTY;

BIOLOGICAL TRANSPORT; CARBOHYDRATE SEQUENCE; CELL MEMBRANE; CIRCULAR DICHROISM; ENKEPHALINS; GLYCOPEPTIDES; MICELLES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MONTE CARLO METHOD; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN CONFORMATION; RECEPTORS, OPIOID;

EID: 0038296015     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja0268635     Document Type: Article

References (110)

1. Marcinowski, K. J.; Shao, H.; Clancy, E. L.; Zagorski, M. G. J. Am. Chem. Soc. 1998, 120, 11 082-11 091.
2. (a) Barrow, C. J.; Zagorski, M. G. Science 1991, 253, 179-182.
3. (b) Fraser, P. E.; Nguyen, J.; Surewicz, W. K.; Kirschner, D. A. Biophys. J. 1991, 60, 1190-1201.
4. (c) Otvos, L. J.; Szendrei, G. I.; Lee, V. M. Y.; Mantsh, H. H. Eur. J. Biochem. 1993, 211, 249-257.
5. (a) Liang, R.; Andreotti, A.; Kahne, D. J. Am. Chem. Soc. 1995, 117, 10 395-10 396.
6. (b) Biondi, L.; Filira, F.; Gobbo, M.; Pavin, E.; Rocchi, R. J. Pept. Sci. 1998, 4, 58-71.
7. Filira, F.; Biondi, L.; Scolaro, B.; Foffani, M. T.; Peggion, E.; Rocchi, R. Int. J. Biol. Macromol. 1990, 12, 41-49.
8. (a) O'Connor, S. E.; Imperiali, B. Chem. Biol. 1998, 5, 427-437.
9. (b) Perczei, A.; Kollat, E.; Hollosi, M.; Fasman, G. D. Biopolymers 1993, 33, 665-685.
10. (c) Bailey, D.; Renhouf, D. V.; Large, D. G.; Warren, C. D.; Hounsell, E. F. Carbohydr. Res. 2000, 324, 242-254.
11. (a) Hollosi, M.; Perczel, A.; Fasman, G. D. Biopolymers 1990, 29, 1549-1564.
12. (b) Butenhof, K. J.; Gerken, T. A. Biochemistry 1993, 32, 2650-2663.
13. (c) Braun, P.; Davies, G. M.; Price, M. R.; Williams, P. M.; Tendler, S. J.; Kunz, H. Biorg. Med. Chem. 1998, 6, 1531-45.
14. (d) Vass, E.; Hollosi, M.; Kveder, M.; Kojic-Prodic, B.; Cudic, M.; Horvat, S. Spectrochim. Acta 2000, 2479-2489.
15. (e) Kindahl, L.; Sandstrom, C.; Craig, A. G.; Norberg, T.; Kenne, L. Can. J. Chem. 2002, 80, 1022-1031.
16. (f) Coltart, D. M.; Royyuru, A. K.; Williams, L. J.; Glunz, P. W.; Sames, D.; Kuduk, S. D.; Schwarz, J. B.; Chen, X. T.; Danishefsky, S. J.; Live, D. H. J. Am. Chem. Soc. 2002, 124, 9833-9844.
17. (a) Wormald, M. R.; Petrescu, A. J.; Pao, Y. L.; Glithero, A.; Elliott, T.; Dwek, R. A. Chem. Rev. 2002, 102, 371-386.
18. (b) Hashimoto, Y.; Toma, K.; Nishikido, J.; Yamamoto, K.; Haneda, K.; Inazu, T.; Valentine, K. G.; Opella, S. J. Biochem. 1999, 38, 8377-8384.
19. (c) Kirnarsky, L.; Prakash, O.; Vogen S. M.; Nomoto, M.; Hollingsworth, M. A.; Sherman S. Biochem. 2000, 39, 12 076-12 082.
20. (d) Seitz, O. Chem. Bio. Chem. 2000, 1, 214-246.
21. (f) Kriss, C. T.; Lou, B.-S.; Szabò, L. Z.; Mitchell, S. A.; Hruby, V. J.; Polt, R. Tetrahedron Asymm. 2000, 11, 9-25.
22. (a) Naganagowda, G. A.; Gururaja, T. L.; Styanarayana, J.; Levine, M. J. J. Peptide Res. 1999, 54, 290-310.
23. (b) Kinarsky, L.; Prakash, O.; Vogen, S. M.; Nomoto, M.; Hollingsworth, M. A.; Shermin, S. Biochemistry 2000, 39, 12 076-12 082.
24. (a) Live, D, H.; Williams, L. J.; Kuduk, S. D.; Schwarz, J. B.; Glunz, P. W.; Chen, X. T.; Sames, D.; Kumar, R. A.; Danishefsky, S. J. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 3489-3493.
25. (b) McManus, A. M.; Otvos, L.; Hoffmann, R.; Craik, D. J. Biochemistry 1999, 38, 705-713.
26. (a) Wilce, J. A.; Otvos, L.; Craik, D. J. Biomed. Pept. Proteins Nucleic Acids 1996, 2, 59-66.
27. (b) Agrawal, P. K.; Jacquinet, J. C.; Krishna, N. R. Glycobiology 1999, 9, 669-677.
28. (c) Kindahl, L.; Sandstrom, C.; Norberg, T.; Kenne, L. Carbohydr. Res. 2001, 336, 319-23.
29. Palian, M. M.; Jacobsen, N. E.; Polt, R. J. Peptide Res. 2001, 58, 180-9.
30. Hughes, J.; Smith, T. W.; Kosterlitz, H. W.; Fothergill, L. A.; Morgan, B. A.; Morris, H. R. Nature (London) 1975, 258, 577-79.
31. For a review on opioid peptide conformations: Spadaccini, R.; Temussi, P. A. Cell. Mol. Life. Sci. 2001, 58, 1572-1582.
32. Kloosterman, D. A.; Goodwin, J. T.; Burton, P. S.; Conradi, R. A.; Stockman, B. J.; Scahill, T. A.; Blinn, J. R. Biopolymers 2000, 53, 396-410.
33. (a) Rudolph-Bohner, S.; Quarzago, D.; Czisch, M.; Ragnarsson, U.; Moroder, L. Biopolymers 1997, 41, 591-606.
34. (b) van der Spoel, D.; Berendsen, H. J. C. Biophys. J. 1997, 72, 2032-2041.
35. (c) Watts, C. R.; Tessmer, M. R.; Kallick, D. A. Lett. Pept. Sci. 1995, 2, 59-70.
36. (d) Zetta, L.; De Marco, A.; Zannoni, G.; Cestaro, B. Biopolymers 1986, 25, 2315-2323.
37. (e) Behnam, B. A.; Deber, C. M. J. Biol. Chem. 1984, 259, 14 935-14 940.
38. Takasu, A.; Houjyou, T.; Inai, Y.; Hirabayashi, T. Biomacromol. 2002, 3, 775-782.
39. (a) Egleton, R. D.; Mitchell, S. A.; Huber, J. D.; Palian, M. M.; Polt, R.; Davis, T. P. J. Pharmacol. Exp. Ther. 2001, 299, 967-72.
40. (b) Williams, S. A.; Abbruscato, T. J.; Szabo, L.; Polt, R.; Hruby, V.; Davis, T. P. Adv. Behav. Biol. 1996, 46(Biology and Physiology of the Blood-Brain Barrier), 69-77.
41. (c) Weber, S. J.; Abbruscato, T. J.; Brownson, E. A.; Lipkowski, A. W.; Polt, R.; Misicka, A.; Haaseth, R. C.; Bartosz, H.; Hruby, V. J.; Davis, T. P. J. Pharmacol. Exp. Ther. 1993, 266, 1649-1655.
42. For reviews of the importance of BBB penetration in CNS drug design, see: (d) Pardridge, W. M. J. Neurochem. 1998, 70, 1781-1792.
43. (e) Egleton, R. D.; Abbruscato, T. J.; Thomas, S. A.; Davis, T. P. J. Pharm. Sci. 1998, 87, 1433-1439.
44. (f) Prokai, L. Prog. Drug Res. 1998, 51, 95-131.
45. (g) Adessi, C.; Soto, C. Current Med. Chem. 2002, 9, 963-978.
46. (a) Polt, R.; Porreca, F.; Szabo, L. Z.; Bilsky, E. J.; Davis, P.; Abbruscato, T. J.; Davis, T. P.; Horvath, R.; Yamamura, H. I.; Hruby, V. J. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 7114-7118.
47. (b) Bilsky, E. J.; Egleton, R. D.; Mitchell, S. A.; Palian, M. M.; Davis, P.; Huber, J. D.; Jones, H.; Yamamura, H. I.; Janders, J.; Davis, T. P.; Porreca, F.; Hruby, V. J.; Polt, R. J. Med. Chem. 2000, 43, 2586-2590.
48. For similar results with glycosylated dermorphins and deltorphins, see: (c) Negri, L.; Lattanzi, R.; Tabacco, F.; Orru, L.; Severini, C.; Scolaro, B.; Rocchi, R. J. Med. Chem. 1999, 42, 400-404.
49. (d) Tomatis, R.; Marastoni, M.; Balboni, G. J. Med. Chem. 1997, 40, 2948-2952.
50. For glycosylated enkephalins capable of transiting the gut, see: Mizuma, T.; Ohta, K.; Awazu, S. Biopharm. Drug Disp. 1998, 19, 605-610.
51. (a) De Marco, A.; Zetta, L.; Menegatti, E.; Guarneri, M. FEBS Lett. 1984, 178, 39-43.
52. (b) Bruch, M. D.; Rizo, J.; Gierasch, L. M. Biopolym. 1992, 32, 1741-1754.
53. (c) Tessmer, M. R.; Meyer, J.-P.; Hruby, V. J.; Kallick, D. A. J. Med. Chem. 1997, 40, 2148-2155.
54. Polt, R.; Szabò, L.; Treiberg, J.; Li, Y.; Hruby, V. J. J. Am. Chem. Soc. 1992, 114, 10 249-10 258.
55. Mitchell, S. A.; Pratt, M. R.; Hruby, V. J.; Polt, R. J. Org. Chem. 2001, 66, 2327-2342.
56. (a) Pelton, J. T.; Gulya, K.; Hruby, V. J.; Duckles, S. P.; Yamamura, H. I. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 236-239.
57. (b) Yamazaki, T.; Ro, S.; Goodman, M.; Chung, N. N.; Schiller, P. W. J. Med. Chem. 1993, 36, 708-719.
58. (a) Bradbury, A. F.; Smyth, D. G.; Snell, C. R. Nature (London) 1976, 260, 165-166.
59. (b) Schiller, P. W.; DiMaio, J. Nature (London) 1982, 297, 74-76.
60. (c) Camerman, A.; Mastropaolo, D.; Karle, I.; Karle, J.; Camerman, N. Nature (London) 1983, 306, 447-450.
61. (a) Gorin, F. A.; Marshall, G. R. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 5179-5183.
62. (b) DiMaio, J.; Bayly, C. I.; Villeneuve, G.; Michel, A. J. Med. Chem. 1986, 29, 1658-63.
63. (c) Hruby, V. J.; Gehrig, C. A. Med. Res. Rev. 1989, 9, 343-401.
64. (d) Massotte, D.; Kieffer, B. L. Essays Biochem. 1998, 33, 65-77.
65. (e) Spadaccini, R.; Temussi, P. A. Cell. Mol. Life Sci. 2001, 58, 1572-82.
66. Porreca, F.; Mosberg, H. I.; Hurst, R.; Hruby, V. J.; Burks, T. F. J. Pharmacol. Exp. Ther. 1984, 230, 341-348.
67. (a) DiMaio, J.; Schiller, P. W. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 7162-7166.
68. (b) DiMaio, J.; Nguyen, T. M.; Lemieux, C.; Schiller, P. W. J. Med. Chem. 1982, 25, 1432-1438.
69. For review: Polt, R.; Palian, M. M. Drugs Future 2001, 26, 561-576.
70. (a) Magzoub, M.; Kilk, K.; Eriksson, L. E. G.; Langel, U.; Graslund, A. Biochim. Biophys. Acta 2001, 1512, 77-89.
71. (b) Schibli, D. J.; Vogel, H. J. Biochem. Cell Biol. 2002, 80, 163-.
72. (c) Grace, R. C. R.; Lynn, A. M.; Cowsik, S. M.; J. Biomol. Struct. Dynam. 2001, 18, 611-625.
73. (d) Albrizio, S.; Carotenuto, A.; Fattorusso, C.; Moroder, L.; Picone, D.; Temussi, P. A.; D'Ursi, A. J. Med. Chem. 2002, 45, 762-769.
74. (a) D'Alagni, M.; Delfini, M.; Di Nola, A.; Eisenberg, M.; Paci, M.; Roda, L. G.; Veglia, G. Eur. J. Biochem. 1996, 240, 540-549.
75. (b) Deber, C. M.; Behnam, B. A. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 61-65.
76. Schwyzer, R.; Sargent, D. F. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 5774-5778.
77. (a) Wienk, H. L. J.; Wechselberger, R. W.; Czisch, M.; deKruijff, B. Biochemistry 2000, 39, 8219-8227.
78. (b) Bryson, E. A.; Rankin, S. E.; Carey, M.; Watts, A.; Pinheiro, T. J. T. Biochemistry 1999, 38, 9758-9767.
79. (c) Deaton, K. R.; Feyen, E. A.; Nkulabi, H. J.; Morris, K. F. Magn. Reson. Chem. 2001, 39, 276-282.
80. Saffman, P. G.; Delbruck, M. Proc. Natl. Acad. Sci. U.S.A. 1975, 72, 3111-3113.
81. For the use of membrane partitioning methods to distinguish bilayer effects from the hydrophobic effect, see: Wimley, W. C.; White, S. H. Biochemistry 1993, 32, 6307-6312.
82. Horvat, S.; Otvos Jr., L.; Urge, L.; Horvat, J.; Cudic, M.; Varga-Defterovic, L. Spectrochim. Acta A 1997, 55, 2347-2352.
83. (a) Shogren, R. L.; Jamieson, A. M.; Blackwell, J.; Fentoft, N. Biopolymers. 1986, 25, 1505-1517.
84. (b) Rose, M. C.; Voter, W. A.; Sage, H.; Brown, C. F.; Kaufman, B. J. Biol. Chem. 1984, 259, 3167-3172.
85. Recent examples: (a) Neidigh, J. W.; Fesinmeyer, R. M.; Prickett, K. S.; Andersen, N. H. Biochem. 2001, 40, 13 188-13 200.
86. (b) Lindberg, M.; Jarvet, J.; Langel, U.; Graeslund, A. Biochem. 2001, 40, 3141-3149.
87. (a) Jarvet, J.; Zdunek, J.; Damberg, P.; Graeslund, A. Biochemistry 1997, 36, 8153-8163.
88. (b) Papavoine, C. H. M.; Konings, R. N. H.; Hilbers, C. W.; van de Ven, F. J. M. Biochemistry 1994, 33, 12 990-12 997.
89. (c) Damberg P.; Jarvet J.; Graslund A. Methods Enzymol. 2001, 339, 271-85.
90. (a) Dyson, H. J.; Rance, M.; Houghten, R. A.; Lerner, R. A.; Wright, P. E. J. Mol. Biol. 1988, 201, 161-200.
91. (b) Dyson, H. J.; Rance, M.; Houghten, R. A.; Wright, P. E.; Lemer, R. A. J. Mol. Biol. 1988, 201, 201-17.
92. For a review on proton exchange in peptides, see: Dempsey, C. Prog. In Nuclear Magn. Reson. Spectrosc. 2001, 39, 135-170.
93. 3-octreotide, see: (a) Schottelius, M.; Wester, H.-J.; Reubi, J. C.; Senekowitsch-Schmidtke, R.; Schwaiger, M. Bioconj. Chem. 2002, 13, 1021-1030.
94. For use of lipid, sugar and liposaccharide-based delivery systems, see: (b) Wong, A.; Toth, I. Curr. Med. Chem. 2001, 8, 1123-1136.
95. For glycosylated RGD-containing peptides with improved biokinetics, see: (c) Haubner, R.; Wester, H.-J.; Burkhart, F.; Senekowitsch-Schmidtke, R.; Weber, W.; Goodman, S. L.; Kessler, H.; Schwaiger, M. J. Nucl. Med. 2001, 42, 326-336.
96. For improved activity of glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39), see: (d) Meurer, J. A.; Colca, J. R.; Burton, P. S.; Elhammer, A. P. Metab. Clin. Exp. 1999, 48, 716-724.
97. (a) Wellings, D. A.; Atherton, E. Methods Enzymol. 1997, 289(Solid-Phase Peptide Synthesis), 44-67.
98. (b) White, Peter D.; Chan, Weng C. Fmoc Solid-Phase Peptide Synthesis 2000, 9-40.
99. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Anal. Biochem. 1970, 34, 2, 595-598.
100. Hoffmann, M. G.; Schmidt, R. R. Liebigs Ann. Chem. 1985, 12, 2403-2419.
101. Bax, A.; Davis D. G. J. Magn. Reson. 1985, 65, 355-360.
102. (a) Piotto, M.; Saudek, V.; Sklenar, V. J. Biolmol NMR 1992, 2, (6) 661-665.
103. (b) Sklenar, V.; Piotto, M.; Leppik, R.; Saudek, V. J Magn. Reson. Ser. A 1993, 102 (2), 241-245.
104. Rucker, Steven P.; Shaka, A. J. Mol. Phys. 1989, 68 (2), 509-17.
105. Romanowski, M.; Zhu, X.; Misicka, A.; Lipkowski, A. W.; Hruby, V. J.; O'Brien, D. F. Biochim. Biophys. Acta 1997, 1329, 245-258.
106. Mohamadi, F.; Richards, N. G.; Guida, W. C.; Liskamp, R.; Lipton, M.; Canfield, C.; Chang, G.; Hendrickson, T.; Still, W. C. J. Comput. Chem. 1990, 11, 440-467.
107. Glennon, T. M.; Zheng, Y. J.; LeGrand, S. M.; Shutzberg, B. A.; Merz, K. M. J. Comput. Chem. 1994, 15, 1019-1040.
108. (a) Venyaminov S. Y.; Gogia Z. V. Eur. J. Biochem. 1982, 126 (2), 299-309.
109. (b) H. Edelhoch Biochemistry 1967, 6 (7), 1948-1954.
110. Lazo, N. D.; Downing, D. T. Biochemistry 1997, 36, 2559-2565.